/ CORRECTION - CONMED Corporation Fourth Quarter 2013 Financial Results Exceed Company Guidance

UTICA, NY--(Marketwired - Feb 13, 2014) - In the news release, "CONMED Corporation Fourth Quarter 2013 Financial Results Exceed Company Guidance," issued earlier today by CONMED Corporation (NASDAQ: CNMD), please be advised that the table headings "Twelve months ended December 31" and "Three months ended December 31" should have been switched for tables RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED INCOME FROM OPERATIONS and RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA. Complete corrected text follows.

CONMED Corporation Fourth Quarter 2013 Financial Results Exceed Company Guidance

UTICA, NY -- Feb 13, 2014 -- CONMED Corporation (NASDAQ: CNMD)

Record Quarterly Sales of $203.4 million
EPS of $0.36
Adjusted EPS of $0.53
Conference Call to be Held at 10:00 a.m. ET Today

CONMED Corporation (NASDAQ: CNMD) today announced financial results for the fourth quarter and year ended December 31, 2013.

"We exited 2013 with strong sales and earnings that exceeded the high end of our guidance for both metrics," said Mr. Joseph J. Corasanti, President and CEO. "Fourth quarter 2013 sales of $203.4 million grew 2.1% on a constant currency basis, compared with a strong performance in the fourth quarter of 2012, and were driven by stronger-than-anticipated sales in Europe and capital equipment products sales. We also achieved sales growth for our single-use and capital products and improved our adjusted gross margins, which led to better-than-expected adjusted earnings per share of $0.53 for the fourth quarter."

Fourth Quarter 2013 Financial Highlights:

Sales were $203.4 million, up 2.1% on a constant currency basis compared with the fourth quarter of 2012; both single-use and capital products grew in excess of 2.0% on an FX neutral basis.
International sales in the fourth quarter of 2013 were $102.7 million, representing 50.5% of total sales. Foreign currency exchange rates, including the effects of the FX hedging program, had a negative impact of $2.0 million in the fourth quarter of 2013.
Diluted earnings per share (GAAP) (EPS) were $0.36 compared with $0.38 in the fourth quarter of 2012. Excluding the Medical Device Excise Tax, (MDET) EPS was $0.40 in the fourth quarter of 2013.
Adjusted diluted earnings per share were $0.53 in the fourth quarter of 2013 compared with $0.52 in the same quarter of 2012. Excluding the MDET, adjusted EPS was $0.57 in the fourth quarter of 2013.
Adjusted EBITDA margin was 18.1%, consistent with the prior year period. Excluding the MDET in 2013, adjusted EBITDA margin for the fourth quarter of 2013 was 18.9%.
The Board of Directors declared a quarterly cash dividend of $0.20 per share, which was paid on January 6, 2014. This quarterly dividend was 33% higher than the prior quarterly cash dividend of $0.15 per share. Based upon the stock price on February 12, 2014, on an annualized basis, the dividend provides investors with a yield of nearly 2%.

Year 2013 Financial Highlights

Sales for 2013 were $762.7 million, up 0.2% on a constant currency basis compared with 2012, resulting from a 0.4% increase in single-use products and a 0.8% decline in capital equipment on an FX neutral basis.
International sales for full year 2013 were $387.2 million, representing 50.8% of total sales. Foreign currency exchange rates, including the effects of the FX hedging program, had a negative impact of $5.7 million on full year 2013.
Diluted earnings per share (GAAP) were $1.28 in the 2013 compared with $1.41 in 2012. Excluding the MDET, EPS was $1.41 in 2013.
Adjusted diluted earnings per share were $1.81 in 2013 compared with $1.80 in 2012. Excluding the MDET, adjusted EPS was $1.94 in 2013.
Adjusted EBITDA margin was 17.2% in 2013 compared with 17.4% in 2012. Excluding the MDET in 2013, adjusted EBITDA margin for the year was 18.0%.

CONMED generated $27.3 million in cash from operating activities in the fourth quarter of 2013. For 2013, the Company generated $80.9 million in cash from operating activities, more than double the net income for the year. The Company repurchased 1,577,800 shares of its common stock for $50.6 million in 2013 at an average price of $32.04 per share.

Outlook

"We are encouraged by the sales growth acceleration we achieved throughout 2013, particularly in our single-use surgical devices, and are optimistic that the positive trends in surgical procedure growth in both the domestic and international markets will support our continued progress," continued Mr. Corasanti. "We have a dynamic financial model and higher-margin single-use products comprise 80% of CONMED's sales with the remaining 20% of sales resulting from surgical devices that fall under the capital expenditure budgets of our hospital customers. Despite the headwinds our capital products faced throughout 2013 due to continued budgetary restraints at hospitals in the United States and public healthcare systems in other countries, we achieved sales growth among these products that exceeded our expectations for the fourth quarter. Looking forward to 2014, we believe that continued modest improvement in the global economy will allow CONMED to achieve annual sales growth and we are reiterating our 2014 sales and adjusted earnings per share guidance. This forecast is based on our expectations for continued sales growth for our single-use products and continued sales improvement for our capital products as the capital equipment replacement cycle normalizes."

For the first quarter of 2014 CONMED expects to achieve:

Sales in the range of $191 to $196 million; and
Adjusted earnings per share between $0.45 and $0.49.

For the full year 2014 CONMED expects to achieve:

Sales in the range of $770 to $780 million;
Adjusted earnings per share between $1.90 and $2.00; and
Approximately 50 basis point improvement in adjusted operating and EBITDA margins.

The adjusted estimates for the first quarter and full year 2014 exclude special items, such as manufacturing restructuring costs expected to be incurred due to relocation of manufacturing activities and patent litigation expense.

Special charges

During the fourth quarter of 2013, the Company continued the on-going consolidation of certain administrative functions and manufacturing activities. Also incurred were litigation costs associated with patent litigation. Further, during the fourth quarter of 2013, the Company incurred a non-cash expense from the settlement of certain pension obligations. Expenses associated with these activities, including severance and relocation costs, amounted to $4.7 million, net of tax, in the fourth quarter of 2013. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For 2014, the Company presently anticipates incurring additional pre-tax special costs of $4.0 - 5.0 million on projects currently in process.

Use of non-GAAP financial measures

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income, adjusted operating income and adjusted earnings per share measure the income of the Company excluding credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income, adjusted operating margin and adjusted earnings per share because management believes that in order to properly understand the Company's short and long-term financial trends, the impact of special items should be eliminated from on-going operating activities. These adjustments for special items are derived from facts and circumstances that vary in frequency and impact on the Company's results of operations. Management uses adjusted net income, adjusted operating income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company's cash flow. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Conference call

The Company will webcast its fourth quarter 2013 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, February 13, 2014. This webcast can be accessed from CONMED's web site at www.conmed.com. Replays of the call will be made available through February 21, 2014.

CONMED profile

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company's 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company's total sales.

Forward Looking Information

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation or litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company's ability to devise and execute strategies to respond to market conditions.



CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(In thousands except per share amounts)
(unaudited)

		Three months ended December 31,				Twelve months ended December 31,
		2012		2013		2012		2013

Net sales		$	201,244	$	203,442	$	767,140	$	762,704
Cost of sales			91,424		89,910		354,245		341,661
Cost of sales, other - Note A			2,533		2,137		7,052		8,626

Gross profit			107,287		111,395		405,843		412,417

Selling and administrative			79,892		82,355		302,469		310,730
Research and development			6,850		6,438		28,214		25,831
Medical device excise tax			-		1,536		-		5,949
Other expense- Note B			3,529		4,885		9,950		13,399
			90,271		95,214		340,633		355,909

Income from operations			17,016		16,181		65,210		56,508

Loss on early extinguishment of debt			-		-		-		263

Interest expense			1,397		1,482		5,730		5,613

Income before income taxes			15,619		14,699		59,480		50,632

Provision for income taxes			4,722		4,472		18,999		14,693

Net income		$	10,897	$	10,227	$	40,481	$	35,939

Per share data:
	Net income
	Basic	$	.38	$	.37	$	1.43	$	1.30
	Diluted		.38		.36		1.41		1.28

	Weighted average common shares
	Basic		28,408		27,644		28,301		27,722
	Diluted		28,727		28,062		28,653		28,114

Note A - Included in cost of sales, other in the three and twelve months ended December 31, 2012 and 2013 are costs related to the consolidation of our production facilities. Also included in the twelve months ended December 31, 2013 are costs associated with the termination of a product offering. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.

Note B - Other expense in the three and twelve months ended December 31, 2012 and 2013 includes a number of adjusted charges. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.



CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
ASSETS

			December 31,
			2012		2013
Current assets:
	Cash and cash equivalents		$	23,720	$	54,443
	Accounts receivable, net			139,124		140,426
	Inventories			156,228		143,211
	Income taxes receivable			2,897		3,805
	Deferred income taxes			11,931		13,202
	Prepaid expenses and other current assets			14,993		17,045
		Total current assets		348,893		372,132

Property, plant and equipment, net				139,041		138,985
Deferred income taxes				1,057		1,183
Goodwill				248,502		248,428
Other intangible assets, net				334,185		319,440
Other assets				7,171		10,340
		Total assets	$	1,078,849	$	1,090,508

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
	Current portion of long-term debt		$	1,050		$	1,140
	Other current liabilities			124,164			110,125
		Total current liabilities		125,214			111,265

Long-term debt				160,802			214,435
Deferred income taxes				99,199			113,199
Other long-term liabilities				86,636			45,290
		Total liabilities		471,851			484,189

Shareholders' equity:
	Capital accounts			256,672			228,002
	Retained earnings			377,907			395,889
	Accumulated other comprehensive loss			(27,581	)		(17,572	)
		Total equity		606,998			606,319

		Total liabilities and shareholders' equity	$	1,078,849		$	1,090,508



CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)

				Twelve months ended
				December 31,
				2012			2013
Cash flows from operating activities:
	Net income			$	40,481		$	35,939
	Adjustments to reconcile net incometo net cash provided by operating activities:
	Depreciation and amortization				46,616			47,867
	Stock-based compensation				5,653			5,593
	Loss on early extinguishment of debt				-			263
	Deferred income taxes				12,946			7,218
		Increase (decrease) in cash flows from changes in assets and liabilities:
			Accounts receivable		1,687			(798	)
			Inventories		3,810			(1,817	)
			Accounts payable		259			4,223
			Income taxes receivable (payable)		(6,651	)		(1,519	)
			Accrued compensation and benefits		767			(71	)
			Other assets		(1,210	)		(5,222	)
			Other liabilities		(9,159	)		(10,727	)
	Net cash provided by operating activities				95,199			80,949

Cash flows from investing activities:
			Payments related to business acquisition and distribution agreement, net of cash acquired		(86,253	)		-
			Proceeds from sale of property		1,836			-
			Purchases of property, plant, and equipment		(21,532	)		(18,445	)
	Net cash used in investing activities				(105,949	)		(18,445	)

Cash flows from financing activities:
			Payments on debt		(54,657	)		(1,277	)
			Proceeds of debt		73,000			55,000
			Payments related to distribution agreement		-			(34,000	)
			Dividends paid on common stock		(12,862	)		(16,696	)
			Payments related to issuance of debt		-			(1,725	)
			Net proceeds from common stock issued under employee plans		10,165			17,264
			Repurchase of common stock		(3,923	)		(50,556	)
			Other, net		(370	)		694
	Net cash provided by (used in) financing activities				11,353			(31,296	)

Effect of exchange rate change on cash and cash equivalents					(2,931	)		(485	)

Net increase (decrease) in cash and cash equivalents					(2,328	)		30,723

Cash and cash equivalents at beginning of period					26,048			23,720

Cash and cash equivalents at end of period				$	23,720		$	54,443



CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME
Three Months Ended December 31, 2012 and 2013
(In thousands except per share amounts)
(unaudited)

		2012			2013

Reported net income		$	10,897		$	10,227

Facility consolidation costs			2,533			2,137

	Total cost of sales		2,533			2,137

Administrative consolidation costs included in other expense			3,053			2,447

Costs associated with purchase of a business			476			-

Patent dispute costs included in other expense			-			995

Pension settlement expense			-			1,443

	Total other expense		3,529			4,885

Adjusted expense before income taxes			6,062			7,022

Provision (benefit) for income taxes on adjusted expenses			(2,074	)		(2,351	)

Adjusted net income		$	14,885		$	14,898

Per share data:

Reported net income
	Basic	$	0.38		$	0.37
	Diluted		0.38			0.36

Adjusted net income
	Basic	$	0.52		$	0.54
	Diluted		0.52			0.53

Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section "Use of Non-GAAP Financial Measures" above.



CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME
Twelve Months Ended December 31, 2012 and 2013
(In thousands except per share amounts)
(unaudited)

		2012			2013

Reported net income		$	40,481		$	35,939

Costs associated with termination of a product offering			-			2,137

Facility consolidation costs			7,052			6,489

	Total cost of sales		7,052			8,626

Administrative consolidation costs included in other expense			6,497			8,750

Costs associated with purchase of Nordic region distributor			704			-

Costs associated with purchase of a business			1,194			-

Legal arbitration and patent dispute costs included in other expense			1,555			3,206

Pension settlement expense			-			1,443

	Total other expense		9,950			13,399

Loss on early extinguishment of debt			-			263

Adjusted expense before income taxes			17,002			22,288

Provision (benefit) for income taxes on adjusted expenses			(5,829	)		(7,473	)

Adjusted net income		$	51,654		$	50,754

Per share data:

Reported net income
	Basic	$	1.43		$	1.30
	Diluted		1.41			1.28

Adjusted net income
	Basic	$	1.83		$	1.83
	Diluted		1.80			1.81



CONMED CORPORATION
RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED INCOME FROM OPERATIONS
(In thousands)
(unaudited)

		Three months ended December 31,				Twelve months ended December 31,
		2012		2013		2012		2013

Reported income from operations		$	17,016	$	16,181	$	65,210	$	56,508

Costs associated with termination of a product offering included in cost of sales			-		-		-		2,137

Facility consolidation costs included in cost of sales			2,533		2,137		7,052		6,489

Administrative consolidation costs included in other expense			3,053		2,447		6,497		8,750

Medical device excise tax			-		1,536		-		5,949

Costs associated with purchase of a business			476		-		1,194		-

Costs associated with purchaseof Nordic region distributor			-		-		704		-

Legal arbitration and patent dispute costs included in other expense			-		995		1,555		3,206

Pension settlement expense			-		1,443		-		1,443

Adjusted income from operations		$	23,078	$	24,739	$	82,212	$	84,482

Operating Margin
	Reported		8.5%		8.0%		8.5%		7.4%

	Adjusted		11.5%		12.2%		10.7%		11.1%

Management has provided the above reconciliation as an additional measure that investors can use to compare financial results between reporting periods. Management believes this reconciliation provides a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.



CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA
(in thousands)
(unaudited)

		Three months ended December 31,				Twelve months ended December 31,
		2012		2013		2012		2013

Net income		$	10,897	$	10,227	$	40,481	$	35,939

Provision for income taxes			4,722		4,472		18,999		14,693

Interest expense			1,397		1,482		5,730		5,613

Loss on early extinguishment of debt			-		-		-		263

Depreciation			4,617		4,952		18,635		18,653

Amortization			7,100		7,228		27,305		28,655

EBITDA		$	28,733	$	28,361	$	111,150	$	103,816

Stock-based compensation			1,538		1,491		5,653		5,593

Costs associated with termination of a product offering included in cost of sales
			-		-		-		2,137

Facility consolidationcosts included in cost of sales			2,533		2,137		7,052		6,489

Administrative consolidationcosts included in other expense			3,053		2,447		6,497		8,750

Costs associated with purchaseof a business			476		-		1,194		-

Costs associated with purchase of Nordic region distributor			-		-		704		-

Legal arbitration and patent dispute costs included in other expense			-		995		1,555		3,206

Pension settlement expense			-		1,443		-		1,443

Adjusted EBITDA		$	36,333	$	36,874	$	133,805	$	131,434

EBITDA Margin
	EBITDA		14.3%		13.9%		14.5%		13.6%

	Adjusted EBITDA		18.1%		18.1%		17.4%		17.2%

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section "Use of Non-GAAP Financial Measures" above.



CONMED CORPORATION
Fourth Quarter Sales Summary
(in millions)

	Three Months Ended December 31,
	2012		2013		Growth		Constant Currency Growth

Orthopedic surgery	$	107.0	$	107.7	0.7	%	2.2	%
General surgery		76.3		76.8	0.7	%	1.2	%
Surgical visualization		17.9		18.9	5.6	%	5.6	%

	$	201.2	$	203.4	1.1	%	2.1	%

Single-use products	$	160.0	$	161.5	0.9	%	2.0	%
Capital products		41.2		41.9	1.7	%	2.4	%

	$	201.2	$	203.4	1.1	%	2.1	%



CONMED CORPORATION
Twelve Months Sales Summary
(in millions)

	Twelve Months Ended December 31,
	2012		2013		Growth		Constant Currency Growth

Orthopedic surgery	$	413.9	$	410.2	-0.9	%	0.1	%
General surgery		286.6		286.7	0.0	%	0.5	%
Surgical visualization		66.6		65.8	-1.2	%	-0.9	%

	$	767.1	$	762.7	-0.6	%	0.2	%

Single-use products	$	611.2	$	609.0	-0.4	%	0.4	%
Capital products		155.9		153.7	-1.4	%	-0.8	%

	$	767.1	$	762.7	-0.6	%	0.2	%